The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...

other industries], biomaterials & green chemicals), food, animal health & agricultural ... Prominent players in the synthetic biology market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany ...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company ... and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck... Soligenix, Inc.

Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...